Spectros
Real-Time Perfusion Monitors

Press Release

# Spectros Attended The American Society of Plastic Surgeons (ASPS) Plastic Surgery 2010 in Toronto at the Metro Toronto Convention Centre, October 1-5, 2010

PORTOLA VALLEY, Calif., Oct. 12 /PRNewswire/ -- Spectros, developer and manufacturer of the T-Stat VLS Tissue Oximeter announces its success in the reconstructive plastic surgery market.

Spectros has begun to see great interest in their VLS white light technology in the reconstructive plastic surgery market. The T-Stat can be easily used to monitor free flaps post operatively. The concept is not new to the market, however T-Stat's patented VLS white light technology is. T-Stat's state-of-the-art second-generation technology yields reproducible and reliable results. Previously, this need was unmet in the clinical world. The need is not only for a noninvasive and easy to use device, but to display an absolute, simple-to-understand and rapid-responding number that surgeons can trust and treat to. Spectros has put great effort into making this happen by collaborating with microsurgeons, vascular surgeons and clinicians.

"The response to the T-Stat in the reconstructive plastic surgery market has been very positive. The advanced technology is providing surgeons a newfound confidence in monitoring their free flaps that wasn't readily available before. Everyone is looking for a noninvasive and easy to use monitoring system, we think we have the answer." stated Elizabeth van Thillo, Director of Marketing.

Spectros attended The American Society of Plastic Surgeons (ASPS) Plastic Surgery 2010 in Toronto at the Metro Toronto Convention Centre, October 1–5, 2010. "This is quickly becoming a forward moving market for Spectros and we plan on focusing our efforts throughout the U.S."

ABOUT SPECTROS: Spectros markets advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's lead T-Stat product became the first FDA-approved medical device for the detection of ischemia, an insufficient blood flow to tissue. Spectros is developing follow-on molecular diagnostic tools for breast and prostate cancer currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern.

ABOUT THERMO FISHER SCIENTIFIC, INC. (TMO): Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics..

(Note: Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns. Certain Spectros applications described above have not been reviewed and approved by the FDA, and are for investigational use only. The "About Thermo Fisher Scientific" text is fair-use quoted from Yahoo Finance Business Summary, May 4, 2009. T-Stat is a registered trademark of the Spectros Corporation.)

*For further information, contact Elizabeth van Thillo, Marketing, Spectros Corporation, at info@spectros.com or 650/529.2865*